文献速递脑血管病认知障碍与痴呆

血管脑健康的试验与治疗:危险因素干预与认知结局

Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes.
PubMed 文献 · Stroke · 2022-01-10

本文综述了血管危险因素干预(降压、降脂、降糖及多领域干预)对认知结局的随机对照试验证据,认为疗效有前景但尚未定论,并指出证据主要来自高收入国家、认知常非主要终点、晚年干预窗口是否最佳不明确、多数试验未检验与年龄/种族/载脂蛋白E的交互作用等方法学局限。

要点

  • 血管危险因素干预对认知结局的疗效证据有前景但尚未定论。
  • 证据主要来自高收入国家,且认知与痴呆常非许多试验的主要终点。
  • 多数试验未检验与年龄、种族、载脂蛋白E等效应修饰因素的交互作用。

核心结论

  • 血管危险因素干预对认知结局的疗效证据有前景但尚未定论,若干方法学局限妨碍解读。

研究设计与样本

  • 综述随机对照试验证据,涵盖降压药、降脂药、糖尿病治疗(降糖药对比安慰剂、强化对比标准血糖控制)及多领域干预。

主要发现

  • 证据主要来自高收入国家,且认知与痴呆常非许多试验的主要终点,认知变化评估常受限。
  • 认知老化过程跨越数十年,晚年窗口治疗是否为痴呆预防的最佳时机尚不明确,而多数试验以老年人为目标人群。
  • 许多试验未把握检验与年龄、种族、载脂蛋白E等效应修饰因素的交互作用,尽管部分试验的亚组分析提示干预成功与否因患者特征而异。

临床怎么用

  • 作者认为,鉴于痴呆病因复杂多因素且个体间危险因素存在差异,可能需要针对多个危险因素和机制的多领域干预。
  • 作者认为,预防干预的长期可持续性将需要个性化方法,数字化健康工具可为此提供便利。
  • 作者认为,在COVID-19大流行期间,干预策略需适应新常态,此时面对面参与受限且公共卫生措施可能改变生活方式,进而影响个体血管风险谱和后续认知下降风险。

局限性

  • 证据主要来自高收入国家。
  • 认知与痴呆常非许多试验的主要终点,认知变化评估常受限。
  • 晚年窗口治疗是否为痴呆预防的最佳时机尚不明确,而多数试验以老年人为目标人群。
  • 许多试验未把握检验与年龄、种族、载脂蛋白E等效应修饰因素的交互作用,尽管部分试验的亚组分析提示干预成功与否因患者特征而异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is robust evidence linking vascular health to brain health, cognition, and dementia. In this article, we present evidence from trials of vascular risk factor treatment on cognitive outcomes. We summarize findings from randomized controlled trials of antihypertensives, lipid-lowering medications, diabetes treatments (including antidiabetic drugs versus placebo, and intensive versus standard glycemic control), and multidomain interventions (that target several domains simultaneously such as control of vascular and metabolic factors, nutrition, physical activity, and cognitive stimulation etc). We report that evidence on the efficacy of vascular risk reduction interventions is promising, but not yet conclusive, and several methodological limitations hamper interpretation. Evidence mainly comes from high-income countries and, as cognition and dementia have not been the primary outcomes of many trials, evaluation of cognitive changes have often been limited. As the cognitive aging process occurs over decades, it is unclear whether treatment during the late-life window is optimal for dementia prevention, yet older individuals have been the target of most trials thus far. Further, many trials have not been powered to explore interactions with modifiers such as age, race, and apolipoprotein E, even though sub-analyses from some trials indicate that the success of interventions differs depending on patient characteristics. Due to the complex multifactorial etiology of dementia, and variations in risk factors between individuals, multidomain interventions targeting several risk factors and mechanisms are likely to be needed and the long-term sustainability of preventive interventions will require personalized approaches that could be facilitated by digital health tools. This is especially relevant during the COVID-19 pandemic, where intervention strategies will need to be adapted to the new normal, when face-to-face engagement with participants is limited and public health measures may create changes in lifestyle that affect individuals' vascular risk profiles and subsequent risk of cognitive decline.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kivipelto M, Palmer K, Hoang TD, et al. Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes. Stroke. 2022. PMID: 35000424. doi:10.1161/STROKEAHA.121.032614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。